SANTA CLARA, Calif. & SAN DIEGO–(BUSINESS WIRE)–Rebus Biosystems Inc, (“Rebus Bio”, “Rebus”), an Illumina Ventures-backed life science technology company creating revolutionary tools to advance spatial omics research, announced today it is partnering with Rosalind, Inc. to co-develop new spatial omics software. The technology will democratize data from single cell spatial analyses from the Rebus Esper™ […]
The throughput of the Rebus Esper has allowed us to explore brain development in a way we never could have before. Getting high sensitivity data from hundreds of thousands of cells in a single experiment enables us to tease apart details of gene regulation that will lead to a better understanding of human brain development.
Cerebrovascular diseases are a leading cause of death and neurologic disability. Further understanding of disease mechanisms and therapeutic strategies requires a deeper knowledge of cerebrovascular cells in humans. We profiled transcriptomes of 181,388 cells to define a cell atlas of the adult human cerebrovasculature, including endothelial cell molecular signatures with arteriovenous segmentation and expanded perivascular […]
Rebus Bio Continues Expansion of Industry-leading Spatial Omics Platform with Breakthrough High-Plex Technology
SANTA CLARA, CA and STOCKHOLM – Dec. 8, 2021 – Rebus Biosystems Inc, (“Rebus Bio”, “Rebus”), an Illumina Ventures-backed life science technology company creating revolutionary tools to advance spatial omics research, today announced that it has acquired the IP and related assay assets of EEL Transcriptomics AB, a privately-held company focused on high-plex spatial transcriptomics with single-cell resolution. Terms […]
Please contact our Rebus support representative for instructions on how to complete the form. Once completed, please email the form back to us.
SANTA CLARA, CA – Rebus Biosystems, Inc., (“Rebus Bio”), an Illumina Ventures-backed life science technology company creating revolutionary tools to advance spatial omics research, today announced Tarif Awad, a highly experienced technical and commercial leader within the world of life sciences, has joined Rebus Bio as VP Scientific Affairs. “Rebus Biosystems has combined powerful Synthetic Aperture Optics microscopy with automated […]
Using an automated, multiplexed single-molecule fluorescent in situ hybridization (smFISH) approach, we validated the expression pattern of area-specific neuronal genes and also discover that laminar gene expression patterns are highly dynamic across cortical regions. Together, our data suggest that early cortical areal patterning is defined by strong, mutually exclusive frontal and occipital gene expression signatures, with resulting […]
SANTA CLARA, Calif. – Rebus Biosystems, Inc., a venture-backed Silicon Valley-based life science technology company creating revolutionary tools to enable spatial omics research without compromise, today announced the appointment of Neil Kennedy as Chief Commercial Officer (CCO) and Scott Kothlow as Chief Financial Officer (CFO). This news comes on the heels of the company’s recent launch of the Rebus EsperTM spatial omics platform […]
SANTA CLARA, Calif. – March 1, 2021 – Rebus Biosystems, Inc., a life science technology company creating revolutionary tools to enable spatial omics research without compromise, today announced the launch of the Rebus EsperTM spatial omics platform. The new spatial omics platform will allow researchers to better understand the biology of tissues and lead to […]
Rebus Biosystems, Inc. Announces $20 Million Series B Financing to Support Commercialization of Automated Spatial Omics Solution
Rebus Biosystems, Inc., a life science technology company building innovative tools to enable spatial omics without compromise, today announced the closing of a $20 million Series B financing round, led by Illumina Ventures and joined by Lifecore Partners, Ncore Ventures, Xolon Invest, CTK Investments, Ray Co., Ltd., Seegene Medical Foundation, LabGenomics Co., Ltd., and Timefolio Asset Management.